Nextrials Adds Multiple Customers And Initiates New Studies Using Its e-Clinical Trial Management Products And Services

Rapid Industry Adoption of Nextrials' Prism Accelerates Company's Growth in Final Months of 2006

San Ramon, CA - Nextrials, Inc., a leader in clinical research software and services, continued to escalate its growth in the latter half of 2006 through the addition of new customers and the initiation of more than a dozen clinical trials using its flagship product, Prism. The rapid adoption of its Internet-based electronic data capture (EDC) technology by pharmaceutical, biotechnology and medical device companies is helping Nextrials maintain the forward momentum it established in 2005, resulting in significant enterprise-wide deployments and Prism's selection for use in larger, multi-site clinical trials in 2006.

Some of Nextrials' newest customers include ArQule, Inc., MAP Pharmaceuticals, Threshold Pharmaceuticals, Allon Therapeutics Inc. and Quark Biotech, Inc., conducting studies ranging from a single site Phase I trial to a multi-year study involving a large number of patients at multiple international sites.

"In 2005, we began to gain real traction for our electronic data capture system within the biopharmaceutical and device research community," noted James Rogers, co-founder and CEO of Nextrials. "In 2006, we responded to industry changes by adding support for the CDISC standard and increasing Prism's interoperability with vendors such as Vitalograph®, Ltd. for providing real-time access to pulmonary function data. This anticipation of customers' needs and requests helps us continue to deliver the service and quality required for broadening the acceptance of e-clinical trial software and services."

Rogers added that Prism's usage in multi-national clinical trials also contributed to the company's success in the latter half of 2006.

"There can be no doubt that there is an increasing need for products such as Nextrials' Prism," noted Michael H. Elliott, founder and president of Atrium Research. "There is greater pressure than ever before for organizational efficiency within clinical trials, demanded not only by a pharmaceutical company's economic stakeholders and the regulatory agencies governing its R&D efforts, but by the real need for novel treatments to enter the marketplace more quickly."

SOURCE: Nextrials, Inc.